AIM
TVRD

Aigen Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Aigen Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-350
Closed -$155K – 1170
2021
Q4 		$155K Buy
+350
New +$176K 0.01% 964
2021
Q2 		– Sell
-394
Closed -$308K – 772
2021
Q1 		$308K Sell
394
-707
-64% -$484K 0.04% 409
2020
Q4 		$600K Buy
1,101
+111
+11% +$58.2K 0.08% 332
2020
Q3 		$453K Sell
990
-1,182
-54% -$687K 0.06% 426
2020
Q2 		$1.34M Buy
+2,172
New +$1.2M 0.17% 175

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aigen Investment Management's TVRD Position: Q1 2022 in Review

Aigen Investment Management sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 350 shares — an estimated $155K sold.

Aigen Investment Management first reported a position in TVRD in Q2 2020 and held it in 5 quarters. The position peaked at $1.34M in Q2 2020. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Aigen Investment Management reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aigen Investment Management sold 350 Tvardi Therapeutics shares in Q1 2022, an estimated $155K.
  • Aigen Investment Management first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 5 quarters.
  • Aigen Investment Management's Tvardi Therapeutics position peaked at $1.34M in Q2 2020.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Aigen Investment Management's 13F filing for Q1 2022, filed 5 May 2022.